<DOC>
	<DOC>NCT02770157</DOC>
	<brief_summary>A study demonstrates the non-inferiority of DA-3002 when compared with Genotropin® in short children born small for gestational age.</brief_summary>
	<brief_title>Efficacy and Safety of DA-3002 in Short Children Borns SGA.</brief_title>
	<detailed_description />
	<criteria>Chronological Age ≥ 4 Before the adolescence, Tuner stage I (breast) Height &lt;3rd percentile for age Normal thyroid function Growth hormone was administered for 12 months or longer in the past Treated with estrogen or adrenal androgens for 12 months or longer in the past Malignancy, CNS Trauma, Psychiatric Disorder endocrine and/or metabolic disorders growth failure caused by other disorders</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>